Last updated: November 3, 2020
Sponsor: University of Washington
Overall Status: Active - Recruiting
Phase
N/A
Condition
Mitochondrial Diseases
Treatment
N/AClinical Study ID
NCT04300608
STUDY00007024
Ages 65-85 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age 65-85 years.
- Ability to attend a 3-hour study visit in Seattle, WA.
- Ability to read and speak English.
- Hoehn & Yahr Stage 2-3. (bilateral disease, not severely disabled.)
Exclusion
Exclusion Criteria:
- Any contra-indication to magnetic resonance imaging
- A history of epilepsy, stroke, brain surgery, or structural brain disease.
- The presence of other serious illnesses
- Current or recent enrollment in a clinical trial involving an investigational productor device.
- Supplementation with NAD, nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and other nutraceuticals designed to target NAD for 30 days prior to baselinestudy visit.
- Current drug or alcohol use or dependence.
- Inability/unwillingness to provide informed consent. (e.g. diagnosis of dementia,confusion about study goals or participation.)
- Acute infection (e.g. upper respiratory, dermal) in the previous 30 days.
- Right limb tremor or dyskinesia that cannot be comfortably controlled for 90 minutes.
Study Design
Total Participants: 30
Study Start date:
February 24, 2020
Estimated Completion Date:
November 30, 2021
Study Description
Connect with a study center
University of Washington
Seattle, Washington 98109
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.